IMEXHS LIMITED (IME)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IME - IMEXHS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -1.68
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.60

27 Sep
2023

0.000

OPEN

$0.60

0.000

HIGH

$0.60

0

LOW

$0.60

TARGET
$1.80 200.0% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . HLA . IDX . IMR . IPD . LDX . MEB . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
IME: 1
Title FY21
Actual		 FY22
Actual		 FY23
Forecast		 FY24
Forecast
EPS (cps) xxx - 8.5 1.0 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 60.0 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A 0.0% xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201720182019202020212022
EPS Basic xxxxxxxxxxxxxxx-8.5
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx17.1 M
Book Value Per Share xxxxxxxxxxxxxxx38.5
Net Operating Cash Flow xxxxxxxxxxxxxxx-2.2 M
Net Profit Margin xxxxxxxxxxxxxxx-17.75 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201720182019202020212022
Return on Capital Employed xxxxxxxxxxxxxxx-18.67 %
Return on Invested Capital xxxxxxxxxxxxxxx-17.68 %
Return on Assets xxxxxxxxxxxxxxx-13.00 %
Return on Equity xxxxxxxxxxxxxxx-18.67 %
Return on Total Capital xxxxxxxxxxxxxxx-13.44 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-2.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201720182019202020212022
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx5 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx2 M
Price To Book Value xxxxxxxxxxxxxxx1.19

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201720182019202020212022
Capex xxxxxxxxxxxxxxx2.0 M
Capex % of Sales xxxxxxxxxxxxxxx11.87 %
Cost of Goods Sold xxxxxxxxxxxxxxx14 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx6 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

01/09/2023

1

Speculative Buy

$1.80

200.00%

First half results for ImExHS were in line with forecasts and Morgans notes positive guidance and outlook commentary.

The broker believes the 30-June closing balances of $2m in cash and debt of -0.9m will be sufficient given a reduced cost base and management's focus on profitable growth from here. It is felt the market is closely watching free cash flow given the stable but meagre cash buffer.

Upgrades are coming for the company's enterprise software product and even small success on contract wins will provide strong positive cash flow momentum, suggests the analyst.

Speculative Buy. The target falls to $1.80 from $1.82.

FORECAST
Morgans forecasts a full year FY23 dividend of 0.00 cents and EPS of 1.00 cents.
Morgans forecasts a full year FY24 dividend of 0.00 cents and EPS of 9.60 cents.
Access Stockbroker Research History >

IME STOCK CHART

FNArena News on IME

1
FNArena Corporate Results Monitor – 01-09-2023

Sep 01 2023 - Australia
2
FNArena Corporate Results Monitor – 01-03-2023

Mar 01 2023 - Australia
3
FNArena Corporate Results Monitor – 31-08-2022

Aug 31 2022 - Australia
4
FNArena Corporate Results Monitor – 02-03-2022

Mar 02 2022 - Australia
5
FNArena Corporate Results Monitor – 31-08-2021

Aug 31 2021 - Australia

Latest Medical Equipment & Devices News

1
Dr Boreham’s Crucible: Painchek

Sep 11 2023 - Small Caps
2
Margins Signal Integral Diagnostics Recovery

Sep 07 2023 - Australia
3
ResMed: Finding A Base?

Aug 15 2023 - Technicals
4
August Turns ResMed Into Nigel NoMates

Aug 09 2023 - Australia
5
Dr Boreham’s Crucible: Lumos Diagnostics

Jun 19 2023 - Small Caps
6
Fisher & Paykel Healthcare: Lower Margin, Higher Spending

May 30 2023 - Australia
7
Dr Boreham’s Crucible: Impedimed

May 08 2023 - Small Caps
8
Treasure Chest: ResMed’s Benevolent Monopoly

May 01 2023 - Treasure Chest
9
Dr Boreham’s Crucible: Volpara Health Technologies

Apr 26 2023 - Small Caps
10
Dr Boreham’s Crucible: SDI

Mar 16 2023 - Small Caps